Please ensure Javascript is enabled for purposes of website accessibility

Why COMPASS Pathways Mushroomed Almost 20% Today

By Howard Smith – Oct 23, 2020 at 4:54PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The trailblazing company studying the use of the psychedelic drug found in magic mushrooms to treat mental health is starting to make waves.

What happened

Shares of biotech start-up COMPASS Pathways (CMPS 3.42%) weren't doing much of anything during this trading day until around 2:30 p.m., when they shot up 17%. Shares then settled back to close up 12% on the day. 

Credit the popularity of CNBC for the move, as chairman, co-founder, and chief executive officer (CEO) George Goldsmith was on to tell his company's story, causing the jump. 

So what 

The company went public one month ago with an initial public offering (IPO) priced at $17 per share, and closed today's session at $38.39 after today's move. CEO Goldsmith went on CNBC this afternoon to discuss the company's psychoactive treatment for depression. 

psychedelic mushrooms against a black background

Image source: Getty Images.

He discussed the company's approach to transforming mental healthcare, using psilocybin, the active ingredient in psychedelic, or "magic" mushrooms.

Now what

The company is currently in Phase 2b of its clinical trials, where the efficacy of the treatment is tested. Goldsmith also noted that the treatment has received breakthrough therapy designation from the U.S. Food & Drug Administration (FDA), allowing it to expedite the development and review of the therapy. 

In addition to the U.S., the UK-based company is doing clinical trials in eight other countries. The company expects to complete and report on its Phase 2b trials at the end of 2021, Goldsmith said in the interview. 

COMPASS initially plans to use its psilocybin therapy for patients with treatment-resistant depression, anxiety, addiction and other mental illnesses. The treatment combines the use of the psychoactive substance with trained therapist psychological support.

Howard Smith has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.